HNN3.0
Register
Register
Register

Project cooperationUpdated on 20 January 2026

ISO 17025 CRO (MENA & EU): Cloud based lab, Pharma Validation, CRMs & Pre-clinical Studies

Strategic Projects Partner at Nawah Scientific

Cairo, Egypt

About

WHO WE ARE: Nawah Scientific is a premier Contract Research Organization (CRO) and ISO 17025 accredited SME operating across the MENA & EU. As a Horizon Europe Associated Country partner, we bring full funding eligibility and a unique "Cloud Lab" infrastructure that processes over 1 million samples annually.

OUR VALUE PROPOSITION: We offer Health Consortiums a "One-Stop-Shop" for Analytical Validation, bridging the gap between drug discovery and clinical trials.

TECHNICAL EXPERTISE (OFFERED SERVICES):

1. In Vivo Pre-clinical Validation (Animal Models):

  • Pharmacokinetics (PK/PD): Bioanalysis via LC-MS/MS for plasma/tissue distribution (Oral, IV, IP) in rodent models.

  • Disease Models: Validated models for Oncology, Metabolic Syndrome, and Inflammation.

  • Safety Studies: Acute/Chronic toxicity testing and Histopathology.

2. In Vitro (Cell-Based) & Molecular Bioassays:

  • Cell-Based: High-throughput screening for Cytotoxicity (MTT/SRB), Cellular Uptake, Permeability (Caco-2), and Flow Cytometry.

  • Molecular: Quantitative Gene Expression (qPCR), Protein Analysis (Western Blot), and ELISA markers.

  • Microbiology: Antiviral (BSL-2/3) and Antibacterial profiling (MIC, Biofilm).

3. Pharma CRMs & Hit-to-Lead Chemistry:

  • Certified Reference Materials: Custom synthesis and certification of pharmaceutical impurities and standards.

  • Characterization: Full structural elucidation using NMR, XRD, and Mass Spectrometry.

4. Advanced Nano-Formulation:

  • Nanotechnology: Design and characterization of Liposomes, PLGA nanoparticles, and Solid Lipid Nanoparticles (SLNs).

WHY PARTNER WITH NAWAH?

  • Dual Reach (MENA & EU): Direct access to diverse biological samples and regional markets via our Egypt and Poland offices.

  • Regulatory Ready: ISO 17025 accreditation ensures data acceptance for regulatory filings.

  • Speed: Centralized Cloud Lab model accelerates TRL advancement.

LOOKING FOR: We are seeking to lead Work Packages in:

  • Pre-clinical Validation (In Vitro/In Vivo)

  • Standardization & Quality Control

  • Bioassay Development & Screening

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

  • Partner seeks Consortium/Coordinator

Organisation

Nawah Scientific

Company (SME)

Cairo, Egypt

Similar opportunities

  • Project cooperation

    Integrated Omics–Driven Diagnostic Innovation Laboratory

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Vel Murugan

    Professor at AZ Board of Regents on behalf of Arizona State University

    Tempe, United States

  • Project cooperation

    Translational NAMs in pharmacology & toxicology for drug profiling

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Nikolas Dietis

    Assistant Professor of Pharmacology at University of Cyprus

    Nicosia, Cyprus

  • Project cooperation

    Clinical Training & Validation Partner for Horizon Health Consortia

    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches

    Luca Takács

    Founder and CEO at LNP Academy

    Budapest, Hungary